tbuckley/cabot-search huggingface dataset:
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Nicole Balin, Miriam Cintron, Paul Ruich, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Roya Coerver-Connolly, Laura Khatiblou, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, Alison Burke, Cassio Lynm, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Staff, Mirna Monal, Tim Melroy, Thalia Moss, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Lara, Audra Lawlor, Matt Herron, Elizabeth Solaro, Geoffrey Flick, Paul Gee Managers, Rick Bell, Michael Mcgraw, Sara Nagy, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, J Neff, Sean O'donnell, Sean Ohlson, Phil O'leary, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van Someren, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Scott Curl, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Suzanne Shuey, Benjamin French, Peter Cummings, Samir Shah, Howard Bauchner, Frederick Rivara, Joyce Lee, Ann Arbor, Cherrie Boyer, San Francisco, Robert Bradley, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Chris Feudtner, Kathleen Janz, Iowa City, Terry Klassen, Michigan Michelle, Huckaby Lewis, Maryland Saiman, New York, York Samir, Martha Sola-Visner, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2014)
SAT0073 Patients with knee osteoarthritis treated by hylan g-f 20 versus usual treatments: a medico-economic, prospective, randomised large scale trial in france, efficacy and safety outcomes
Authors: A Kahan, E Guemas, PL Lleu
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To evaluate the efficacy and safety of Hylan G-F 20 over 9 months in the treatment of patients with knee osteoarthritis (OA). <h3>Methods</h3> Patients with radiographically proven knee OA, pain on movement ³ 40 mm (VAS) and treated by at least two 10-day NSAIDs courses or by slow-acting anti-OA drugs within the previous 3 or 2 months respectively were enrolled by 81 centres (21 hospitals and 60 private rheumatologists). After stratification on known OA risk factors (patients? age, BMI,...), patients were centrally randomised in Synvisc (S) or in usual treatment (UT) groups. S-patients were treated by 3 intraarticular injections of Hylan GF 20 one week apart and encouraged to stop or spare any other OA treatments. If needed S-patients could be treated by Synvisc in both knees. Efficacy and safety data were collected at baseline, day 28, months 3, 6 and 9. <h3>Results</h3> Out of 518 patients randomised, 506 (253 per group) were treated and evaluable. Demographic data (mean age = 66/66 years, female = 67/68%, BMI = 28/28 kg/m<sup>2</sup>, bilateral knee OA = 72/76% in S vs UT groups respectively) were comparable at baseline. Forty-five S-patients (18%) were treated in both knees. S-patients showed a better improvement than UT-patients regarding all primary and secondary efficacy outcomes. More especially, mean (SD) changes in S-group versus UT-group were ?3.6 (4.1) vs ?1.6 (4.0) for Lequesne Index, ? 20.1 (19.3) vs ? 8.2 (20.5) mm for WOMAC total score and ? 37.4 (22.3) vs ? 24.4 (24.0) mm for pain on movement. Therefore additional improvements (p = 0.0001) were observed in S-group for Lequesne Index (+ 18.7%), WOMAC total (+ 24.4%), and pain on movement (+ 21.1%). In S-group, global efficacy was assessed as good/satisfactory by 74% of patients and by 76% of investigators versus 51% and 48% respectively in UT-group, p &lt; 0.0001. Transient local adverse events (pain, swelling) after Synvisc injections were reported in 11.8% of injections. Gastrointestinal adverse events related to OA treatment were less frequently reported in S-patients (3.5%) as compared to UT-patients (11.9%) (p &lt; 0.001). <h3>Conclusion</h3> This large-scale study confirms the efficacy and safety of viscosupplementation by Synvisc in knee OA over a 9-month follow-up. <h3>Acknowledgement</h3> Synvisc Experts Group: Prs. Bardin T., Dougados M., Kahan A. (Paris), Mazières B (Toulouse), Trèves R. (Limoges), Vignon E. (Lyon), Drs Auvinet B. (Laval), Naim C. (Marseille), Rossignol O. (Fontenay).
Use of Thin Layer Chromatography in the Diagnosis of Poisoning
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Authors: K Mckee, S Pandey, N Sarma
Journal: JAMA Neurology (2015)

Kassardjian and colleagues describe the clinical, serologic, and electrophysiologic characteristics of necrotizing autoimmune myopathy (NAM), compare patient subgroups, and determine clinical outcome predictors.Clinical, electrophysiologic, and pathologic characteristics were collected and compared among patient subgroups, and predictors of response to treatment were identifi ed by univariate logistic regression.They report that NAM was idiopathic in half of this cohort with clinical and histopathologically defi ned disease and that, in the remainder, NAM was associated with statin medication, cancer, or connective tissue disease.Editorial perspective in support of these data is provided by Matthew N. Meriggioli, MD.
Intraluminal Pressure Waves of the Stomach in Dogs Studied by Endoradiosondes
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preface
Authors: Terry Gordon, Emma Karey, Meghan Rebuli, Yael-Natalie Escobar, Ilona Jaspers, Lung Chen
Journal: The Annual Review of Pharmacology and Toxicology (1978)

Since the spread of tobacco from the Americas hundreds of years ago, tobacco cigarettes and, more recently, alternative tobacco products have become global products of nicotine addiction. Within the evolving alternative tobacco product space, electronic ...Read More
[Re: Ä Pilot Study of Urinary Estrogen Metabolites (16α-OHE 1 and 2-OHE 1 ) in Postmenopausal Women with and without Breast Cancer"]: Response
Authors: Giske Ursin, Stephanie London, Malcolm C. Pike
Journal: Environmental Health Perspectives (1998)

Second, the authors excluded patients with advanced breast cancer because of the significant mortality in this group.Third, the authors argued that exdusion of women with specific exposures is unlikely to have introduced bias.However, we are not told how many of the original study group were successfully contacted, what proportion had died, and what proportion of those recontacted, and eligible, agreed to participate in the second study.Did these proportions differ between cases and controls?Fourth, in addition to the possibility of selection bias due to differential recruitment in the second study, the lack of a significant difference between cases and controls may be due to the restriction of the study to early stage cancer.In the study by Kabat et al. (2), among postmenopausal women the ratio of 2-OHE1/16a-OHE1 was strongly and inversely associated with breast cancer.However, this association was driven pri- marily by a strong association with later stage cancer (stages III and IV).Finally, in the small sample for which the results were reported, adjustment for breast cancer risk factors (induding age at menarche, age at first pregnancy, parity, family history of breast cancer, and ethnicity) was apparently not carried out.This is critical because the matched-pair design of the original study was not maintained in the current study.We look forward to the full report, which will hopefully provide more detailed information on these questions.It should be clearly understood that these results, as they now stand, are in no way inconsistent with our hypothesis that the metabolite ratio is a valid biochemical marker for breast cancer.
Painful knee in a young girl
Authors: J. E. Meyer
Journal: JAMA (1970)

Dr. Meyer: The patient is a 19-year-old girl who was well until one year prior to admission, when she noted the gradual onset of intermittent, mild pain in her right knee. This continued to be an annoying but tolerable symptom until she fell on the knee one month prior to admission, after which the pain was constant but still mild. The findings of roentgenographic examination of the knee at this time prompted referral to the hospital for evaluation. Results of physical examination were entirely normal. There was no pain on deep palpation of the distal right femur. There was no swelling, joint effusion, or redness. <h3>Discussion</h3> Dr. Richard C. Pfister: Dr. Shea, would you discuss this case? Dr. Thomas E. Shea: The roentgenograms of the right knee show a 5 × 7-cm lesion in the distal femur (Fig 1). The abnormality is metaphyseal in location, extending into the diaphysis and
BOOK REVIEWS
Authors: H. I. PASS
Journal: JNCI Journal of the National Cancer Institute (1992)

BOOK REVIEWS Get access Malignant Mesothelioma Douglas W. Henderson , Keith B. Shilkin , Suzanne Le P. Langlois , Darrel Whitaker , eds. New York : Hemisphere Publ. , 1992 . 383 pp., illus. $99.50 HARVEY I. PASS HARVEY I. PASS Thoracic Oncology Section Surgery Branch National Cancer Institute National Institutes of Health Bldg.10, Rm. 2B07 Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 11, 3 June 1992, Pages 895–896, https://doi.org/10.1093/jnci/84.11.895-a Published: 03 June 1992
Kitchen Drawer
Authors: Elspeth Cameron Ritchie
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemiology of Gastrointestinal Cancer
Authors: Irving J. Selikoff
Journal: Environmental Health Perspectives (1974)

Some 99,000 new cases of cancer of the colon are expected next year, an incidence rate higher than that for both cancer of the lung and cancer of the breast. Evidence from geographic pathology suggests that some environmental factors play a strong role in its etiology. Data obtained in the 1959 survey of one million people by the American Cancer Society and followed since, has failed to show correlation with any of the large number of factors listed. It is suggested that the etiology is one of multiple factors. The synergistic effect of exposure to asbestos and cigarette smoking in the production of bronchogenic carcinoma is demonstrated by data on cohorts of insulation workers. There was also a modest increase in the number of deaths from gastrointestinal cancer in asbestos workers, but smoking did not seem to act in synergistic fashion at that site, except perhaps in the esophagus. Deaths from cancer occurred almost entirely after a period of 20 years or more from initial exposure. The death rate from cancer tended to increase with duration of exposure, but a distinct rise over the expected was seen in those who had been exposed less than one year to amosite dust.
THE FUNCTION OF THE PATHOLOGIST AS A CONSULTANT
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QuickStats:Percentage* of Adults with Fair or Poor Health,† by Home Ownership Status§ and Age Group — National Health Interview Survey,¶ United States, 2014
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

With 95% confidence intervals indicated with error bars.† Defined by family respondent's answer to the following question on the family core questionnaire: "Would you say [your] health in general is very good, good, fair, or poor?" § Defined by family respondent's answer to the following question on the family core questionnaire: "Is this house/apartment owned or being bought, rented, or occupied by some other arrangement by [you or someone in your family]?" ¶ Estimates are based on household interviews of a sample of the noninstitutionalized U.S.
Organized action: management advisory councils
Authors: J. M. Danielson
Journal: JAMA (1966)

If the hospital is becoming the focal point of health care, and if the quality of its care is to continue to be vested totally in the hands of the physician, then the most intimate partnership must necessarily exist between the executive branch and the professional branch of the institution. How can the physician become a part of management? One principle is clear: a management advisory council within the hospital that involves the physician leadership as well as the executive officer seems a requirement. This is a council where the only criterion for the adoption of an idea is its own validity. No dictate but consensus—no pecking order to threaten assigned official prerogatives, or votes to cause division. Ironically, in an age when the prerogatives of management are held to be so priceless, hospital executives need to return to the sharing of these prerogatives with the physicians; yet the physicians
A Textbook of Pharmacology.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diuretics and Coronary Heart Disease
Authors: Ray W. Gifford
Journal: JAMA (1985)

<h3>To the Editor.—</h3> Holme et al<sup>1</sup>present a subgroup analysis from the Oslo Hypertension Study,<sup>2</sup>relating coronary events in hypertensive patients with and without ECG abnormalities. These patients were given either a placebo or specific antihypertensive therapy, which included a diuretic in most cases. The authors conclude that in the subgroup of hypertensives with pretreatment abnormal ECGs, the trend toward increased coronary events, which was noted in the Multiple Risk Factor Intervention Trial (MRFIT)<sup>3</sup>was also observed in their study. They note, however, that their analysis lacks statistical power because of the small number of men studied and caution that conclusions should be drawn with great care from their data. Unfortunately, many physicians may not read this article as carefully as they should and may erroneously conclude that the data from MRFIT and the Oslo Study were significant and that the use of diuretics in hypertensive patients
Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer.
Authors: Joseph Gligorov, Nicolas Janus, Catherine Daniel, Philippe Beuzeboc, Isabelle Ray-Coquard, Jean-Baptiste Rey, Christelle Jouannaud, Jean-Philippe Spano, Jean Christophe Thery, Jean F. Morere, Francois Goldwasser, Olivier Mir, Florian Scotte, Stephane Oudard, Michel Azizi, Richard Dorent, Gilbert Deray, Vincent Launay-Vacher
Journal: Journal of Clinical Oncology (2013)

e12504 Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Methods: This multicentric, prospective, observational study evaluated the renovascular safety of AVD in pts naive from any AVD, conducted in 7 centres in France, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), diabetes, HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit. Results: 1,124 pts were included; 402 breast cancer (BC) pts received bevacizumab. Median age at inclusion was 55 years. Visceral, bone and cerebral metastasis frequencies were 74.7, 5.1 and 2.5%, respectively. HTN prevalences: 12.4%. Baseline renal assessment retrieved: Pu 23.9%, Hu 16.2%, mean aMDRD 96.4 ml/min/1.73m 2 and 14 pts with aMDRD&lt;60. The incidence of de novo Pu and HTN during f/u was 61.7 and 16.8% (Table). 69.7 % of pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 75.7% afterwards improved/normalized. No grade 4 Pu has been reported. Renal function remained stable with a mean aMDRD of 96.2 at the end of f/u. 7.4% had grade 2-3 SCr increase (no grade 3-4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of bevacizumab in BC patients showed that 1) TMA is rare, 2) Grade 3 Pu developed in 4.6% of pts, with no grade 4, 3) less than 17% developed HTN, and 4) aMDRD was stable. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]